Page 481 - Read Online
P. 481

Maner et al. J Cancer Metastasis Treat 2020;6:37  I  http://dx.doi.org/10.20517/2394-4722.2020.60                        Page 33 of 40

               Furthermore, the incorporation of artificial intelligence data analysis of trends between the various
               pathways can help improve management of cutaneous malignancies by clinicians. Once these conditions
               are elucidated, oncologists can develop prospective personalized dynamic genetic testing for identifying the
               critical set of active oncogenetic pathways that need to be disrupted at particular moments. This process
               would then transform the lives of individual patients suffering from multiple cutaneous malignancies
               around the world.


               DECLARATIONS
               Authors’ contributions
               Wrote, final edited and revised the manuscript: Maner BS, Dupuis L, Su A, Jueng JJ, Harding TP,
               Meisenheimer VII J, Siddiqui FS, Hardack MR, Aneja S, Solomon JA
               Contributed to Figure 10: Su A
               Contributed to Figures 1, 2, 3, 6, 7, 8, 12 and reference organization: Meisenheimer VII J


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.

               Conflicts of interest
               None that may be perceived as influencing the representation or interpretation of review other than Dr.
               James A. Solomon was a clinical investigator of Vismodegib clinical trials and expanded access program-
               funds paid to his employer and has been a paid consultant by Genentech, Sun Pharmaceuticals, Mayne
               Pharmaceuticals.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.

               REFERENCES
               1.   Ley RD. Photoreactivation in humans. Proc Natl Acad Sci U S A 1993;90:4337.
               2.   Feehan RP, Shantz LM. Molecular signaling cascades involved in nonmelanoma skin carcinogenesis. Biochem J 2016;473:2973-94.
               3.   Sample A, He YY. Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 2018;34:13-24.
               4.   de Gruijl FR. Photocarcinogenesis: UVA vs. UVB radiation. Skin Pharmacol Appl Skin Physiol 2002;15:316-20.
               5.   Craig S, Earnshaw CH, Virós A. Ultraviolet light and melanoma. J Pathol 2018;244:578-85.
               6.   Patrick MH. Studies on thymine-derived UV photoproducts in DNA--I. Formation and biological role of pyrimidine adducts in DNA.
                   Photochem Photobiol 1977;25:357-72.
               7.   Lee JH, Budanov AV, Karin M. Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metabolism 2013;18:792-801.
               8.   Budanov AV, Karin M. p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008;134:451-60.
               9.   Holick MF. Biological effects of sunlight, ultraviolet radiation, visible light, infrared radiation and vitamin D for health. Anticancer Res
                   2016;36:1345-56.
               10.  Leavitt E, Lask G, Martin S. Sonic hedgehog pathway inhibition in the treatment of advanced basal cell carcinoma. Curr Treat Options
                   Oncol 2019;20:84.
               11.  Bolognia JJ, Jorizzo JL, Rapini RP. Dermatology. Philadelphia: Elsevier Saunders; 2012.
               12.  Xie J, Murone M, Luoh SM, Ryan A, Gu Q, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature
   476   477   478   479   480   481   482   483   484   485   486